Shuttle Pharmaceuticals Holdings, Inc. — Q1 2023 Form 10-Q Summary
Business Context and Reporting Period
The filing covers the unaudited three months ended March 31, 2023, compared with the three months ended March 31, 2022. Shuttle is a development-stage pharmaceutical company developing radiation-sensitizing cancer therapies, HDAC inhibitors and related oncology technologies. Its lead programs include Ropidoxuridine and SP-2-225. The company has no commercial revenue and remains dependent on financing, grants and research collaborations.
Financial Metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Total operating expenses | $1.545 million | $638,396 | Up 142% |
| Research and development | $1.011 million | $295,915 | Up 242% |
| General and administrative | $166,348 | $13,769 | Up 1,108% |
| Legal and professional | $367,624 | $328,712 | Up 12% |
| Net loss | $975,097 | $681,839 | Up 43% |
| Basic and diluted loss per share | $0.07 | $0.07 | No change |
| Cash flow from operating activities | $(1.338) million | $(624,607) | Greater use of cash |
| Cash flow from investing activities | $(2.954) million | $0 | New investment activity |
| Cash flow from financing activities | $3.044 million | $525,715 | Up 479% |
Revenue and gross margins are not meaningful because the company generated no revenue. The operating loss was $1.545 million. Other income of $569,683, substantially driven by a $1.241 million non-cash gain from the change in fair value of derivative liabilities, reduced the reported net loss to $975,097.
At March 31, 2023, cash and cash equivalents were $7.169 million, marketable securities were $2.992 million and total current assets were $10.372 million. Current liabilities were $1.388 million, producing working capital of $8.984 million. Total liabilities were $3.530 million and stockholders’ equity was $6.906 million.
Debt included a $4.3 million Alto convertible note issued in January 2023, recorded net of discounts at $1.369 million across current and non-current portions, plus a $1.390 million derivative liability. The note matures March 11, 2025, may be extended by the noteholder, and has an effective interest rate estimated at approximately 250% because of its financing terms and discounts. The note is secured by the company’s assets and intellectual property and includes conversion, redemption and acceleration features.
Material Changes Versus the Prior Comparable Period
- R&D expense increased $714,893, primarily due to expanded program spending following the 2022 public offering and the January 2023 convertible financing. The increase included a $300,000 milestone payment to TCG GreenChem for IPdR development and manufacturing work.
- General and administrative expense increased $152,579, primarily due to higher insurance, director fees and corporate filing fees.
- Interest expense increased to $599,331 from $145,553, including substantial amortization of debt discounts associated with the Alto financing.
- The company invested $2.954 million in trading marketable securities, principally U.S. Treasury bonds, during the quarter.
- The company raised $3.935 million in gross proceeds, or approximately $3.590 million net of fees, through the Alto convertible note and warrant transaction. It also repaid related-party notes and accrued interest.
- Common shares outstanding increased from 13,603,129 at December 31, 2022 to 13,654,127 at March 31, 2023. The company issued 50,998 shares to settle convertible-note principal and interest.
Outlook, Risks, Contingencies and Unusual Items
- Management stated that existing cash resources, including the 2022 public offering proceeds and the January 2023 convertible financing, were expected to fund planned operations through the second half of 2024. The company continues to expect substantial future spending on research, clinical development, regulatory preparation, manufacturing and potential commercialization.
- The company has never generated positive operating cash flow and expects to require additional financing. Management cautioned that financing may be unavailable or dilutive and that insufficient funding could delay or curtail the business plan.
- The Alto note permits repayment in cash or, subject to conditions, registered common shares. Its conversion price can be reduced based on market prices, creating potential dilution. The associated warrant covers 1,018,079 shares, and total warrants outstanding at March 31, 2023 were 1,446,155.
- The Alto transaction gives the investor security interests and liens over company assets and intellectual property. A springing deposit account control arrangement could allow the investor to control specified bank-account funds following a default.
- The $1.390 million derivative liability is a Level 3 fair-value measurement based on Monte Carlo modeling. Changes in assumptions, including volatility, discount rates and implied VWAP, may materially affect reported earnings.
- Subsequent to quarter-end, the company issued 150,660 shares to settle $110,250 of principal and $58,021 of accrued interest. In May 2023, it amended the Alto transaction documents and agreed, subject to shareholder approval, to seek authorization for up to an additional $10 million of convertible notes and related warrants. The amendment also provided for release of $1.5 million of cash collateral.
- The company disclosed material weaknesses in internal control over financial reporting related to accounting for significant unusual transactions, the financial statement close process and financial reporting reviews. Management concluded that disclosure controls and procedures were not effective as of March 31, 2023.
- Drug candidates remain subject to extensive preclinical, clinical and FDA approval requirements. The filing highlights risks involving trial delays or failures, regulatory approval, intellectual property protection, manufacturing and future financing.
- In May 2023, the USPTO approved a patent application relating to cancer therapies using halogenated thymidines and thymidine phosphorylase inhibitors with radiation.
Important Facts for Investors to Verify
- Confirm the terms, amortization schedule, conversion mechanics, security interests, default provisions and potential dilution from the Alto convertible note and warrants.
- Assess whether the stated funding runway through the second half of 2024 remains valid after operating losses, debt repayments, research spending and the proposed additional financing.
- Monitor cash burn, marketable securities, restricted or collateralized cash and the release of the $1.5 million collateral described in the subsequent-event disclosure.
- Review the magnitude and remediation status of the disclosed material weaknesses in internal controls.
- Track clinical, regulatory and manufacturing milestones for Ropidoxuridine, SP-2-225 and IPdR, including the company’s ability to obtain required FDA approvals.
- Reconcile subsequent share issuances and any future conversions or warrant exercises with the company’s fully diluted share count.
- Evaluate the sensitivity of reported earnings and liabilities to Level 3 derivative valuation assumptions.